Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Doward LC, McKenna SP, Meads DM, Jovell AJ, Fisk J, Eckert BJ. The international development of patient reported outcome indices for multiple sclerosis. Poster presented at the 2006 Sixteenth Meeting of the European Neurological Society; May 2006. Lausanne, Switzerland. [abstract] J Neurol. 2006; 253(Suppl 2):125.